Enhanced interlekin 18 therapeutic - Bright Peak Therapeutics
Alternative Names: modified IL-18 therapeutic - Bright Peak TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Bright Peak Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Immunostimulants; Interleukin 18 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 29 Jul 2020 Preclinical trials in Cancer in Switzerland (unspecified route) prior to July 2020
- 28 Jul 2020 Bright Peak Therapeutics in licenses technology from Swiss Federal Institute of Technology